Marksans Pharma arm Relonchem bags UK MHRA marketing nod for oral solution to treat epilepsy
Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Levetiracetam Relonchem 100 mg/mL Oral Solution from the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (UK MHRA).
Levetiracetam, a medication used for the treatment of epilepsy, helps in managing specific seizure types.
The product will be manufactured at the Group’s UK manufacturing facility.
Read also: Marksans Pharma bags USFDA nod for Esomeprazole Magnesium Delayed Release Capsules
Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.